Benedicto David C.

Chief Financial Officer

Adamis Pharmaceuticals Corporation

US, San Diego [HQ]

CIK 1864646

Data Source

We automatically created this profile. The information was aggregated based on earnings call transcripts, insider forms and DEF 14A statements.

Latest Information

43,478

Price per Share :

$0.78

Equivalence :

$33,912.84

Transaction History

S

Form 4

43,478 Shares After Transaction

Value : $34,347.62

Sold $10,707.66

Transaction Date : 12/01/21
- Footnotes
- Form 4
Footnotes:
#1 The shares were sold to pay the withholding and tax obligations relating to the issuance of shares upon the vesting of RSUs previously granted to the reporting person.

#2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.7784 to $0.7925, inclusive. The reporting person undertakes to provide Adamis Pharmaceuticals Corporation, any security holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

#3 Includes shares of common stock beneficially owned and shares of common stock issuable upon vesting of restricted stock units previously reported in Table 1 of Form 4.
S

Form 4

39,875 Shares After Transaction

Value : $24,323.75

Sold $2,197.83

Transaction Date : 03/18/22
- Footnotes
- Form 4
Footnotes:
#1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The shares were sold to pay the withholding and tax obligations relating to the issuance of shares following the vesting of RSUs previously granted to the reporting person.

#2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $0.5954 to $0.6143, inclusive. The reporting person undertakes to provide Adamis Pharmaceuticals Corporation, any security holder of Adamis Pharmaceuticals Corporation, or the staff of the Securities Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.

#3 Includes shares of common stock beneficially owned and shares of common stock issuable upon vesting of restricted stock units previously reported in Table 1 of Form 4.